Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Actinium Pharmaceuticals, Inc. (NYSE:ATNM) have received an average recommendation of “Moderate Buy” from the six research firms that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $11.43.

A number of research analysts recently issued reports on the company. Maxim Group reduced their price objective on Actinium Pharmaceuticals from $30.00 to $5.00 and set a “buy” rating for the company in a research report on Tuesday. Cantor Fitzgerald restated an “overweight” rating and set a $21.00 price target on shares of Actinium Pharmaceuticals in a research report on Tuesday, April 30th. StockNews.com downgraded shares of Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday. Stephens initiated coverage on shares of Actinium Pharmaceuticals in a research note on Tuesday, May 14th. They set an “overweight” rating and a $25.00 target price for the company. Finally, B. Riley lowered shares of Actinium Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price target for the company from $16.00 to $2.00 in a research note on Wednesday.

Actinium Pharmaceuticals Price Performance

Actinium Pharmaceuticals stock opened at $2.41 on Friday. The firm has a market capitalization of $71.78 million, a price-to-earnings ratio of -1.41 and a beta of 0.20. Actinium Pharmaceuticals has a 12 month low of $1.33 and a 12 month high of $10.24.

Actinium Pharmaceuticals (NYSE:ATNM) last released its quarterly earnings data on Monday, August 5th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.02. On average, analysts anticipate that Actinium Pharmaceuticals will post -1.57 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Actinium Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ATNM. Sanders Morris Harris LLC acquired a new stake in shares of Actinium Pharmaceuticals in the first quarter valued at $78,000. Rhumbline Advisers grew its stake in shares of Actinium Pharmaceuticals by 23.4% in the 2nd quarter. Rhumbline Advisers now owns 39,656 shares of the company’s stock worth $293,000 after purchasing an additional 7,525 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Actinium Pharmaceuticals by 28.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 86,401 shares of the company’s stock worth $639,000 after purchasing an additional 19,035 shares in the last quarter. Virtu Financial LLC raised its holdings in shares of Actinium Pharmaceuticals by 319.2% in the 1st quarter. Virtu Financial LLC now owns 82,029 shares of the company’s stock worth $642,000 after purchasing an additional 62,459 shares in the last quarter. Finally, Vanguard Group Inc. lifted its stake in Actinium Pharmaceuticals by 6.0% during the first quarter. Vanguard Group Inc. now owns 1,446,326 shares of the company’s stock valued at $11,325,000 after purchasing an additional 82,113 shares during the last quarter. 27.50% of the stock is owned by institutional investors.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.